MultipEL Studies
- Address
- Bengelsdorfstr. 5, 22179 Hamburg, Germany
MultipEL Studies - Multiple Sclerosis Research Center
MultipEL Studies is a specialized research center dedicated to advancing treatment options for patients with multiple sclerosis. The center focuses on long-term safety and effectiveness evaluations of innovative therapies, particularly in relapsing multiple sclerosis (RMS), contributing valuable data on extended treatment protocols and patient outcomes.
- Long-term safety and tolerability studies of disease-modifying therapies
- Open-label extension trials for relapsing multiple sclerosis
- Subcutaneous biologic therapy administration and monitoring
The center's research emphasizes comprehensive evaluation of immunomodulatory treatments, including subcutaneous administration protocols with monthly dosing schedules. By conducting open-label extension studies, MultipEL Studies provides critical insights into the sustained effectiveness and safety profiles of therapies beyond initial clinical trial periods, helping to establish optimal long-term management strategies for patients living with relapsing forms of multiple sclerosis.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 45 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 45 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MultipEL Studies
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Postpartum B-Cell Depletion in Infants Exposed to Ocrelizumab In Utero in Mothers with Multiple Sclerosis or Clinically Isolated Syndrome | F. Hoffmann-La Roche AG | Phase III | Not Recruiting | Nov 2021 | May 2025 |
IMP list
lock Showing 1 of 45 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| A/Darwin/6/2021(H3N2)-Like Strain (A/Darwin/11/2021, Wild Type) | 1 | Unknown | 2019-01-30 | 2019-01-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.